Longer treatment with cancer drug following removal of GI tumor results in improved survival
Among patients with a high risk of recurrence of a gastrointestinal stromal tumor following surgery for its removal, patients who received imatinib (a drug to treat certain cancers) for 3 years instead of 1 had improved recurrence-free survival and overall survival, according to a study in the March 28 issue of JAMA.
"Gastrointestinal stromal tumors (GIST) are usually found in the stomach or the small intestine but can occur at any site along the gastrointestinal tract and rarely elsewhere within the abdominal cavity," according to background information in the article. "The malignancy potential of GIST varies from negligible in micro GIST to aggressive cancer." Treatment with imatinib for 12 months after surgery has improved recurrence-free survival (RFS), although recurrence of GIST is common during the first years following discontinuation of treatment, suggesting that 12 months of administration may be too short a time period.
Heikki Joensuu, M.D., of the Helsinki University Central Hospital, Helsinki, Finland, and colleagues examined whether adjuvant (following surgery) imatinib treatment for longer than 3 years might be beneficial compared to 1 year of administration for GIST patients who were considered to have a high risk of GIST recurrence. The randomized trial included patients with KIT (a gene)-positive GIST removed at surgery who were entered into the study between February 2004 and September 2008. Two hundred patients were assigned to the 12-month group and 200 to the 36-month group from 24 centers located in Finland, Germany, Norway, and Sweden. Patients were randomized to receive imatinib, 400 mg per day, orally for either 12 months or 36 months, started within 12 weeks of surgery.
The researchers found that recurrence-free survival was longer in the 36-month group compared with the 12-month group (5-year RFS, 65.6 percent vs. 47.9 percent). Fewer patients assigned to 36 months of imatinib administration died during the follow-up as compared with those assigned to the 12-month group (12 vs. 25, respectively), and overall survival was longer in the 36-month group (5-year survival, 92.0 percent vs. 81.7 percent, respectively).
The authors also found that a larger proportion of patients discontinued imatinib in the 36-month group for reasons other than GIST recurrence compared with the 12-month group (51 [25.8 percent] vs. 25 patients [12.6 percent], respectively; the reasons were adverse effect, patient preference, tumor histology not GIST, and other or unspecified reason). Almost all study patients had at least 1 adverse event recorded; most events were graded mild in severity.
The researchers add that the effect on overall survival was based on a relatively small number of deaths, and the study patients will continue to be followed up to confirm the overall survival benefit. "Because GIST recurrence is frequent after discontinuation of adjuvant imatinib, studies that evaluate still longer treatments are warranted, as are studies that address novel agents and their combinations."
Charles D. Blanke, M.D., F.R.C.P.C., of the University of British Columbia and British Columbia Cancer Agency, Vancouver, Canada, writes in an accompanying editorial that the U.S. Food & Drug Administration recently granted regular approval for adjuvant use of imatinib in adults after resection of KIT-positive GISTs, and that the results of this trial has established 3 years of 400 mg of imatinib per day as the new standard of care for postoperative treatment of patients with resected high-risk GISTs.
"Some clinicians will use imatinib for a longer period, perhaps choosing to treat patients indefinitely. Investigators and clinicians alike will increasingly face the question of best postoperative duration of treatment with cytostatic, biologic targeted agents. However, correlative science provides little guidance. Laboratory biomarker studies may eventually provide information about which patients are unlikely to have recurrence, and thus are not capable of benefitting from any adjuvant therapy, but questions about curability or duration will not be answered by preclinical trials. As pathway-driven adjuvant therapy becomes more prolonged, increasing patients' tolerance of even low-grade toxicities will be critical to improve their adherence to expensive treatments that could last for decades."
More information: JAMA. 2012;307:1265-1272.
Provided by JAMA and Archives Journals
- Predicting patient response to gleevec in gastrointestinal stromal tumors Apr 21, 2009 | not rated yet | 0
- Drug shows promise as new treatment for gut tumor Jan 11, 2010 | not rated yet | 0
- Targeted drug helps leukemia patients who do not benefit from initial therapy Feb 27, 2012 | not rated yet | 0
- Thalidomide shows efficacy as adjuvant therapy for hepatocellular carcinoma patients Apr 02, 2011 | not rated yet | 0
- Report describes first targeted therapy to produce remission of metastatic melanoma Apr 18, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
Marie Curie's leukemia
May 13, 2013 Does anyone know what might be the cause of Marie Curie's cancer
- More from Physics Forums - Medical Sciences
More news stories
In a new study described in the journal Oncogene, researchers reveal how a key player in cell growth, immunity and the inflammatory response can be transformed into a primary contributor to tumor growth.
Cancer 4 hours ago | not rated yet | 0 |
A new study conducted using extensive medical records of over one million Israeli adolescents before military service shows clearly how exposure to the Israeli sun of young, light-skinned children increases substantially ...
Cancer 6 hours ago | not rated yet | 0
A new measure of the heterogeneity – the variety of genetic mutations – of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer. In the May 20 issue ...
Cancer 10 hours ago | not rated yet | 0
Researchers at Mayo Clinic have developed a promising method to distinguish between pancreatic cancer and chronic pancreatitis—two disorders that are difficult to tell apart. A molecular marker obtained from pancreatic ...
Cancer 10 hours ago | not rated yet | 0
The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...
Cancer May 19, 2013 | not rated yet | 0
While the effects of acute stroke have been widely studied, brain damage during the subacute phase of stroke has been a neglected area of research. Now, a new study by the University of South Florida reports that within a ...
55 minutes ago | not rated yet | 0 |
A new report suggests that improved health care and significant reductions in drug costs might be attained by breaking up the age-old relationship between physicians and drug company representatives who promote the newest, ...
58 minutes ago | not rated yet | 0
As high schoolers prepare for final exams, teens nationwide may be tempted to use a "study drug"—a prescription stimulant or amphetamine—to gain an academic edge. But a new University of Michigan poll shows only one in ...
20 minutes ago | not rated yet | 0
Food microbiology laboratories continue to submit false negative results and false positive results on a routine basis. A retrospective study of nearly 40,000 proficiency test results over the past 14 years, presented today ...
44 minutes ago | not rated yet | 0
Posterior fossa subdural hematoma (PFSDH) is a serious and rare condition in newborns, generally occurring after difficult deliveries. But with appropriate treatment, there's an excellent chance of good long-term outcomes ...
47 minutes ago | not rated yet | 0
National guidelines recommend that at-risk women be screened for elevated cholesterol levels to reduce their chances of developing cardiovascular disease. But who is 'at risk?' The results of a study by investigators ...
57 minutes ago | not rated yet | 0